본문 바로가기
KERD
논문KCI 등재

Recent advances in multiple myeloma: a Korean perspective

Jae Hoon Lee|Junshik Hong
대한내과학회 (The Korean Association Of Internal Medicine)|2016.09|The Korean Journal of Internal Medicine|제31권 제5호|pp. 820-834|DOI http://dx.doi.org/10.3904/kjim.2015.408

2

조회

0

다운로드

6

인용

0

참고문헌

키워드

KoreaEpidemiologyDiagnosisMultiple myelomaNeoplasm staging
주제분류내과학

초록

Epidemiologically, multiple myeloma (MM) is a malignant disorder of plasma cells with a higher incidence among Western populations than among Asians. However, there is growing evidence of a recent increase in the age-standardized incidence rate (ASR) of MM in Asian countries, particularly Korea. Application of novel agents has resulted in significant improvement of treatment outcomes, and the advances are ongoing with the recent introduction and U.S. Food and Drug Administration’s approval of newer agents, including carfilzomib, ixazomib, elotuzumab, and daratumumab. In concert with the technical advances in the cytogenetic and molecular diagnostics of MM, modifications of its diagnosis and staging system have been attempted for better risk stratification. The modified diagnostic criteria from the International Myeloma Working Group in 2014 enabled a strategy of more active treatment for some patients with smoldering MM, with an ultra-high risk of progression, and fine-tuned the definition of end-organ damage, known as CRAB (hypercalcemia, renal insufficiency, anemia, and bone lesions). Considering Korea’s trend of aging at an unprecedented rate, we can expect that the ASR of MM will maintain a gradual increase for many years to come; therefore, MM will be a cancer of critical importance from both medical and socioeconomic perspectives in Korea.

Abstract

Epidemiologically, multiple myeloma (MM) is a malignant disorder of plasma cells with a higher incidence among Western populations than among Asians. However, there is growing evidence of a recent increase in the age-standardized incidence rate (ASR) of MM in Asian countries, particularly Korea. Application of novel agents has resulted in significant improvement of treatment outcomes, and the advances are ongoing with the recent introduction and U.S. Food and Drug Administration’s approval of newer agents, including carfilzomib, ixazomib, elotuzumab, and daratumumab. In concert with the technical advances in the cytogenetic and molecular diagnostics of MM, modifications of its diagnosis and staging system have been attempted for better risk stratification. The modified diagnostic criteria from the International Myeloma Working Group in 2014 enabled a strategy of more active treatment for some patients with smoldering MM, with an ultra-high risk of progression, and fine-tuned the definition of end-organ damage, known as CRAB (hypercalcemia, renal insufficiency, anemia, and bone lesions). Considering Korea’s trend of aging at an unprecedented rate, we can expect that the ASR of MM will maintain a gradual increase for many years to come; therefore, MM will be a cancer of critical importance from both medical and socioeconomic perspectives in Korea.

참고문헌 (117)

  1. Kumar SK, "Improved survival in multiple myeloma and the impact of novel therapies", Blood, 111, pp.2516~2520 (2008)
  2. Kumar SK, "Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients", Leukemia, 28, pp.1122~1128 (2014)
  3. Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
  4. Siegel RL, "Cancer statistics, 2015", CA Cancer J Clin, 65, pp.5~29 (2015)
  5. Kyle RA, "A long-term study of prognosis in monoclonal gammopathy of undetermined significance", N Engl J Med, 346, pp.564~569 (2002)
  6. Kyle RA, "Prevalence of monoclonal gammopathy of undetermined significance", N Engl J Med, 354, pp.1362~1369 (2006)
  7. Blade J, "Clinical practice: monoclonal gammopathy of undetermined significance", N Engl J Med, 355, pp.2765~2770 (2006)
  8. Kyle RA, "Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management", Leukemia, 24, pp.1121~1127 (2010)
  9. Rajkumar SV, "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma", Lancet Oncol, 15, pp.e538~e548 (2014)
  10. Park HK, "Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population", Am J Hematol, 86, pp.752~755 (2011)
  11. 이윤규, "Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort", Cancer Research and Treatment, 47(2), pp.215~220 (2015), 대한암학회[DOI]
  12. Riedel DA, "The epidemiology of multiple myeloma", Hematol Oncol Clin North Am, 6, pp.225~247 (1992)
  13. Lee JH, "Multiple myeloma in Korea:past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party", Int J Hematol, 92, pp.52~57 (2010)
  14. Huang SY, "Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25years and higher prevalence of extramedullary myeloma in patients younger than 55 years", Cancer, 110, pp.896~905 (2007)
  15. Khuhaprema T, "Cancer in Thailand. Vol. 7" (2013), Ministry of Public Health and Ministry of Education
  16. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
  17. Eun-Hye Park, "Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012", Blood Research, 50(4), pp.204~217 (2015), 대한혈액학회
  18. Rosenberg PS, "Future distribution of multiple myeloma in the United States by sex, age, and race", ethnicity, 2015, pp.125, 410~412
  19. "Life table 2014" (1996)[URL]
  20. Kyung-Rae Hyun, "Population Aging and Healthcare Expenditure in Korea", Health Economics, 25(10), pp.1239~1251 (2016), Wiley-Blackwell[DOI]
  21. Hernandez JM, "Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma", Br J Haematol, 127, pp.159~164 (2004)
  22. Attal M, "A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome", N Engl J Med, 335, pp.91~97 (1996)
  23. Child JA, "High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma", N Engl J Med, 348, pp.1875~1883 (2003)
  24. Moreau P, "All transplantation-eligible patients with myeloma should receive ASCT in first response", Hematology Am Soc Hematol Educ Program, 2014, pp.250~254 (2014)
  25. Orlowski RZ, "Novel agents for multiple myeloma to overcome resistance in phase III clinical trials", Semin Oncol, 40, pp.634~651 (2013)
  26. Singhal S, "Antitumor activity of thalidomide in refractory multiple myeloma", N Engl J Med, 341, pp.1565~1571 (1999)
  27. Rajkumar SV, "Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group", J Clin Oncol, 24, pp.431~436 (2006)
  28. Richardson PG, "A phase 2study of bortezomib in relapsed, refractory myeloma", N Engl J Med, 348, pp.2609~2617 (2003)
  29. Richardson PG, "Bortezomib or high-dose dexamethasone for relapsed multiple myeloma", N Engl J Med, 352, pp.2487~2498 (2005)
  30. Orlowski RZ, "Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression", J Clin Oncol, 25, pp.3892~3901 (2007)
  31. San Miguel JF, "Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma", N Engl J Med, 359, pp.906~917 (2008)
  32. Sonneveld P, "Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials", J Clin Oncol, 31, pp.3279~3287 (2013)
  33. Dimopoulos M, "Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma", N Engl J Med, 357, pp.2123~2132 (2007)
  34. Weber DM, "Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America", N Engl J Med, 357, pp.2133~2142 (2007)
  35. Benboubker L, "Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma", N Engl J Med, 371, pp.906~917 (2014)
  36. McCarthy PL, "Lenalidomide after stem-cell transplantation for multiple myeloma", N Engl J Med, 366, pp.1770~1781 (2012)
  37. Kumar SK, "Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study", Leukemia, 26, pp.149~157 (2012)
  38. San Miguel J, "Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial", Lancet Oncol, 14, pp.1055~1066 (2013)
  39. Kortuem KM, "Carfilzomib", Blood, 121, pp.893~897 (2013)
  40. Stewart AK, "Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma", N Engl J Med, 372, pp.142~152 (2015)
  41. Dimopoulos MA, "Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study", Lancet Oncol, 17, pp.27~38 (2016)
  42. Moreau P, "Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and", or refractory multiple myeloma (RRMM): the phase 3 tourmaline-MM1 study, 2015, pp.126, 727~
  43. Moreau P, "Oral therapy for multiple myeloma: ixazomib arriving soon", Blood, 124, pp.986~987 (2014)
  44. San-Miguel JF, "Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial", Lancet Oncol, 15, pp.1195~1206 (2014)
  45. Lonial S, "Elotuzumab therapy for relapsed or refractory multiple myeloma", N Engl J Med, 373, pp.621~631 (2015)
  46. Lokhorst HM, "Targeting CD38 with daratumumab monotherapy in multiple myeloma", N Engl J Med, 373, pp.1207~1219 (2015)
  47. Mateos MV, "Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma", N Engl J Med, 369, pp.438~447 (2013)
  48. Dispenzieri A, "Smoldering multiple myeloma requiring treatment: time for a new definition?", Blood, 122, pp.4172~4181 (2013)
  49. International Myeloma Working Group, "Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group", Br J Haematol, 121, pp.749~757 (2003)
  50. Ghobrial IM, "How I treat smoldering multiple myeloma", Blood, 124, pp.3380~3388 (2014)
  51. Kyle RA, "Clinical course and prognosis of smoldering(asymptomatic)multiple myeloma", N Engl J Med, 356, pp.2582~2590 (2007)
  52. Landgren O, "Multiple myeloma precursor disease: current clinical dilemma and future opportunities", Semin Hematol, 48, pp.1~3 (2011)
  53. Rajkumar SV, "Diagnosis of smoldering multiple myeloma", N Engl J Med, 365, pp.474~475 (2011)
  54. Kastritis E, "Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease", Leukemia, 27, pp.947~953 (2013)
  55. Larsen JT, "Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma", Leukemia, 27, pp.941~946 (2013)
  56. Hillengass J, "Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma", J Clin Oncol, 28, pp.1606~1610 (2010)
  57. Weber DM, "Prognostic features of asymptomatic multiple myeloma", Br J Haematol, 97, pp.810~814 (1997)
  58. Regelink JC, "Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review", Br J Haematol, 162, pp.50~61 (2013)
  59. Hutchison CA, "The pathogenesis and diagnosis of acute kidney injury in multiple myeloma", Nat Rev Nephrol, 8, pp.43~51 (2012)
  60. Avet-Loiseau H, "Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project", Leukemia, 27, pp.711~717 (2013)
  61. Palumbo A, "Revised international staging system for multiple myeloma: a report from International Myeloma Working Group", J Clin Oncol, 33, pp.2863~2869 (2015)
  62. 김철수, "The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea", The Korean Journal of Internal Medicine, 30(5), pp.675~683 (2015), 대한내과학회[DOI]
  63. Mikhael JR, "Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013", Mayo Clin Proc, 88, pp.360~376 (2013)
  64. Chng WJ, "IMWG consensus on risk stratification in multiple myeloma", Leukemia, 28, pp.269~277 (2014)
  65. Kuiper R, "Prediction of high-and low-risk multiple myeloma based on gene expression and the International Staging System", Blood, 126, pp.1996~2004 (2015)
  66. Palumbo A, "Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report", Blood, 125, pp.2068~2074 (2015)
  67. Lee H, "A case of alpha2 plasmacytoma", New Med J, 2, pp.1113~1117 (1959)
  68. Kang DY, "Statistical studies on multiple myeloma in Korea: preliminary report", Korean J Hematol, 7, pp.31~40 (1972)
  69. Kim HJ, "Multiple myeloma in Korea: clinical analysis and treatment results in 61 cases", Korean J Med, 28, pp.770~779 (1985)
  70. Jung JW, "A clinical study on multiple myelom", J Korean Cancer Assoc, 27, pp.869~879 (1995)
  71. Kim TY, "Combination chemotherapy with vincristine, melphalan, and prednisolone for multiple myeloma", Korean J Med, 45, pp.1~12 (1993)
  72. Kim HJ, "Combination chemotherapy for the treatment of multiple myeloma", J Korean Cancer Assoc, 24, pp.577~585 (1992)
  73. Lee JT, "Phase 2 trial of VAD (vincristine, doxorubicin, and dexamethasone) in refractory multiple myeloma", Korean J Hematol, 31, pp.145~153 (1996)
  74. Lee JH, "High dose chemotherapy with autologous stem cell transplantation in multiple myeloma", Korean J Hematol, 34, pp.306~316 (1999)
  75. 방수미, "High Dose Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation as a First Line Treatment for Multiple Myeloma: a Korean Multicenter Study", Journal of Korean Medical Science, 18(5), pp.673~678 (2003), 대한의학회
  76. Bang SM, "Preliminary report of risk-based approach in Korean patients with newly diagnosed multiple myeloma", Blood, 104, pp.4911~ (2004)
  77. 이근욱, "A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma", Journal of Korean Medical Science, 20(4), pp.598~602 (2005), 대한의학회
  78. DoYeunKim, "Salvage Therapy with Thalidomide in Patients with Relapsed or Refractory Multiple Myeloma", Blood Research, 37(4), pp.1~264 (2002), 대한혈액학회
  79. Oh HS, "Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial", Int J Hematol, 76, pp.465~470 (2002)
  80. Bang SM, "A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma", Int J Hematol, 83, pp.309~313 (2006)
  81. Kim HJ, "Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial", Ann Hematol, 91, pp.249~256 (2012)
  82. Yang DH, "Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study", Clin Lymphoma Myeloma Leuk, 10, pp.62~67 (2010)
  83. Kim JS, "Sequential high-dose dexamethasone and response adapted PAD (bortezomib, adriamycin, dexamethasone) or VAD (vincristine, adriamycin, dexamethasone) induction chemotherapy followed by high-dose chemotherapy with autologous stem cell transplantation for newly diagnosed multiple myeloma:open-labelled, multicenter phase 2 study (KMM-94study): interim analysis", Blood, 118, pp.2044~ (2011)
  84. Eom HS, "Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)", Ann Hematol, 89, pp.489~497 (2010)
  85. 이호섭, "Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation", Journal of Korean Medical Science, 28(1), pp.80~86 (2013), 대한의학회
  86. Lee SS, "Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety", Ann Hematol, 89, pp.905~912 (2010)
  87. Kim YK, "Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study", Ann Hematol, 89, pp.475~482 (2010)
  88. Kim K, "Lenalidomide with dexamethasone treatment for relapsed", refractory myeloma patients in Korea-experience from 110 patients, 2014, pp.93, 113~121
  89. Kim JS, "Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation", Biol Blood Marrow Transplant, 15, pp.463~470 (2009)
  90. Min CK, "A multicenter comparison of autologous stem cell transplantation followed by reduced-intensity allogenic stem cell transplantation with tandem autologous stem cell transplantation in multiple myeloma", Blood, 110, pp.940~ (2007)
  91. Kim SJ, "Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry", Acta Haematol, 122, pp.200~210 (2009)
  92. Oh S, "Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study", Ann Hematol, 93, pp.1353~1361 (2014)
  93. Kim HJ, "Myelomatous pleural effusion of multiple myeloma: characteristics and outcome", Blood, 114, pp.3874~ (2009)
  94. Kim MK, "Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients", Ann Oncol, 22, pp.411~416 (2011)
  95. Bang SM, "Molecular cytogenetic analysis of Korean patients with Waldenstrom macroglobulinemia", Cancer Genet Cytogenet, 197, pp.117~121 (2010)
  96. Jun HJ, "Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: results of multicenter analysis", Am J Hematol, 88, pp.52~55 (2013)
  97. Kim HJ, "Osteonecrosis of the jaw in multiple myeloma patients: incidence and characteristics in Korean patients", Blood, 114, pp.4956~ (2009)
  98. Kim SJ, "Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma", Clin Lymphoma Myeloma, 8, pp.237~240 (2008)
  99. Kim SJ, "Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP)Retrospective Study", Jpn J Clin Oncol, 41, pp.353~357 (2011)
  100. Koh Y, "Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide", Ann Hematol, 89, pp.201~206 (2010)
  101. Bang SM, "Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma", Cancer Genet Cytogenet, 168, pp.124~132 (2006)
  102. 강성호, "한국인에서 다발성 골수종 발생 위험과 NQO1 유전자 다형성의 연관성", Annals of Laboratory Medicine, 26(2), pp.71~76 (2006), 대한진단검사의학회
  103. Kang SH, "Protective role of CYP1A1*2A in the development of multiple myeloma", Acta Haematol, 119, pp.60~64 (2008)
  104. Kim TY, "Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction", Br J Haematol, 146, pp.270~281 (2009)
  105. Kim SY, "Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation", Biol Blood Marrow Transplant, 17, pp.810~820 (2011)
  106. Park G, "Concurrent p16 methylation pattern as an adverse prognostic factor in multiple myeloma: a methylation-specific polymerase chain reaction study using two different primer sets", Ann Hematol, 90, pp.73~79 (2011)
  107. Lee JJ, "Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates", Leuk Lymphoma, 48, pp.2022~2031 (2007)
  108. Kim SK, "Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens", Ann Hematol, 88, pp.1113~1123 (2009)
  109. Yang DH, "The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma", Leuk Res, 33, pp.665~670 (2009)
  110. Yang DH, "Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells", Ann Hematol, 89, pp.795~801 (2010)
  111. Avet-Loiseau H, "Impact of FISH and cytogenetics on overall and event free survival in myeloma: an IMWG analysis of 9,897 patients", Blood, 114, pp.743~ (2009)
  112. Palumbo A, "International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation", Leukemia, 23, pp.1716~1730 (2009)
  113. Richardson PG, "Management of treatment-emergent peripheral neuropathy in multiple myeloma", Leukemia, 26, pp.595~608 (2012)
  114. Kim K, "Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study", Am J Hematol, 89, pp.751~756 (2014)
  115. Tan D, "Management of multiple myeloma in Asia: resource-stratified guidelines", Lancet Oncol, 14, pp.e571~e581 (2013)
  116. Tan D, "The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian Myeloma Network", Leuk Res, 37, pp.1070~1076 (2013)
  117. Baz R, "Response adapted lenalidomide based therapy for newly diagnosed (ND) standard risk older adults with multiple myeloma (MM): an international collaboration", Blood, 122, pp.3201~ (2013)

관련 논문AI추천

21세기 다발골수종의 단일 기관 현실 세계 경험김신, 강은희, 박정선, 서철원, 이경민, 조형우대한내과학회 · 대한내과학회지2022 · 제97권 제2호Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications박용, 고영일, 김미소, 김병수, 김인호, 성화정, 신정훈, 육정환, 윤성수, 최철원대한내과학회 · The Korean Journal of Internal Medicine2017 · 제32권 제4호The characteristics of Korean elderly multiple myeloma patients aged 80 years or overHee-Jeong Cho, Ji Yoon Jung, Joon Ho Moon, Mi Hwa Heo, Min Kyoung Kim, Sang Hwan Lee, Sung Hwa Bae, Young Rok Do, Yunhwi Hwang대한내과학회 · The Korean Journal of Internal Medicine2025 · 제40권 제1호Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice민창기, 이호섭대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제5호Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience김기현, 김선희, 장미애, 정현애대한진단검사의학회 · Annals of Laboratory Medicine2018 · 제38권 제3호The Effect of Disability on the Diagnosis and Treatment of Multiple Myeloma in Korea: A National Cohort Study권지현, 김소영, 김연용, 박종헌, 박종혁, 신동욱, 엽경은, 이기형, 한혜숙대한암학회 · Cancer Research and Treatment2020 · 제52권 제1호

이 간행물의 다른 논문 (26건)

Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice이호섭, 민창기pp. 809-819Endoscopic gastritis, serum pepsinogen assay, and Helicobacter pylori infection이선영pp. 835-844Current status of managing diabetes mellitus in KoreaDae Jung Kim, Kyoung Hwa Happ. 845-850Lung injury as an extra-intestinal manifestation of inflammatory bowel diseaseKyung Sik Parkpp. 851-852Investigation of pulmonary involvement in inflammatory bowel disease in an experimental model of colitisI. Metin Ciris, Recep Sutcu, Yıldıran Songur, Bunyamin Aydin, Necla Songur, Oğuzhan Aksu, Altug Senolpp. 853-859
원문 보기